79 results about "Interleukin 6" patented technology

The invention discloses an anti-human inflammatory factor interleukin 6 monoclonal antibody and an application thereof. When the monoclonal antibody is prepared, an adopted immunogen is a human inflammatory factor interleukin 6 antigen, and an amino acid sequence of the human inflammatory factor interleukin 6 antigen comprises a sequence as shown in SEQ ID NO: 1. A group of monoclonal antibodies specifically combined with antigens is constructed based on the IL-6 antigens. The IL-6 monoclonal antibody has strong binding capacity with an IL-6 antigen in a clinical sample, has no cross reaction with other proteins, has good specificity and affinity compared with a commercial antigen, can be effectively applied to ELISA and a dry-type immunofluorescence method, has good detection linearity, precision, stability and accuracy, and can be widely applied to the field of immunoassay. The antibody can be combined with the antigen to serve as a detection reagent raw material combination, and has clinical detection advantages.

The invention belongs to the technical field of electrochemical sensors, and particularly relates to an in-situ self-amplification nucleic acid-based flexible wound sensor and a preparation method thereof. The sensor comprises a flexible substrate, a gold layer and a nucleic acid sensing layer, the nucleic acid sensing layer comprises a tumor necrosis factor-alpha sensor, an interleukin 6 sensor, a transforming growth factor beta1 sensor, a vascular endothelial growth factor sensor, a temperature sensor, a pH sensor, a reference electrode and a counter electrode; the tumor necrosis factor-alpha sensor, the interleukin 6 sensor, the transforming growth factor beta1 sensor and the vascular endothelial growth factor sensor are all modified with rigid DNA tetrahedrons with hairpin DNA H2 and corresponding hairpin DNA H1. The sensor provided by the invention has antifouling and anti-degradation effects; finally, in-situ nucleic acid amplification on the flexible biosensing interface is realized by virtue of a hydrophilic / hydrophobic confinement effect and an auxiliary nucleic acid pre-fixation strategy, so that the detection sensitivity is improved.

The invention belongs to the technical field of in-vitro diagnosis and rapid detection, and relates to an interleukin 6 and procalcitonin joint detection kit, a preparation method and a detection method, the interleukin 6 and procalcitonin joint detection kit comprises a Ra1 reagent, a Ra2 reagent, an Rb1 reagent, an Rb2 reagent and a substrate solution; the Ra1 reagent is an interleukin 6 antibody magnetic bead labeling solution, and is prepared from a biotin labeled interleukin 6 first antibody solution and a streptavidin magnetic bead solution; the Ra2 reagent is a procalcitonin antibody magnetic bead labeling solution, and is prepared from a biotin labeled procalcitonin first antibody solution and a streptavidin magnetic bead solution; the Rb1 reagent is prepared from an alkaline phosphatase labeled interleukin 6 second antibody solution; the Rb2 reagent is prepared from a second procalcitonin antibody solution labeled by horse radish peroxidase; the substrate solution comprises a first substrate solution and a second substrate solution. The detection sensitivity can be improved, the detection time is shortened, the detection efficiency is improved, and the operation is simple.

The invention relates to application of indole-3-propionic acid in preparation of drugs for preventing and treating pulmonary ischemia reperfusion injury. Through in-vivo animals, the inventor finds that indole-3-propionic acid can reduce the lung injury score in a concentration-dependent manner, reduce the wet weight / dry weight ratio of lungs, relieve active oxygen accumulation after lung ischemia reperfusion, and reduce the levels of total protein, tumor necrosis factor alpha and interleukin 6 in alveolar lavage fluid; the cell level also shows that the indole-3-propionic acid can improve the vitality of alveolar epithelial cells after ischemia / reperfusion injury simulation in a concentration-dependent manner, reduce release of inflammatory factors such as tumor necrosis factors alpha, interleukin 6 and interleukin 1beta, and reduce accumulation of active oxygen in the cells. Results of integrating in-vitro cells and in-vivo animals show that the indole-3-propionic acid has the effect of preventing and treating the pulmonary ischemia reperfusion injury and has a good clinical application prospect.

The invention provides an application of a compound as shown in a formula I, cis-trans isomers, enantiomers, diastereoisomers, racemes, solvates, hydrates or pharmaceutically acceptable salts or prodrugs of the compound in preparation of drugs for prevention, alleviation, adjuvant therapy or treatment of lung injury, and application of the compound in preparation of drugs for prevention, alleviation, adjuvant therapy or treatment of lung injury in preparation of drugs for prevention, alleviation, adjuvant therapy or treatment of lung injury in preparation of drugs for prevention, alleviation, adjuvant therapy or treatment of lung injury. The compound shown in the formula I can obviously reduce proinflammatory cytokine tumor necrosis factor alpha (TNF-alpha) and interleukin 6 (IL-6) of an acute lung injury rat model, improve infiltration of inflammatory cells (including mononuclear / macrophage, lymphocyte and neutrophil) in lung tissues, improve pathological injury of the lung tissues, improve lung functions, and improve the curative effect of the lung. The above results show that the compound represented by the formula I can be used for prevention, alleviation, adjuvant therapy or treatment of lung injury, especially acute lung injury or a combined disease thereof or acute respiratory distress syndrome or a combined disease thereof.

The present disclosure provides a method of identifying a tumor for immunotherapy. The method comprises culturing tumor cells obtained from a subject; exposing the tumor cells to nanoparticles comprising a positively-charged surface and an interior comprising (i) a core and (ii) at least two nucleic acid layers, wherein each nucleic acid layer is positioned between a cationic lipid bilayer; and measuring interferon-alpha and interleukin 6 (and optionally Chemokine (C-C motif) ligands 4) produced by the tumor cells. A method of treating a subject with cancer also is provided. The method comprises culturing tumor cells from the subject; exposing the tumor cells to the nanoparticles; measuring interferon-alpha and interleukin 6 (and optionally Chemokine (C-C motif) ligands 4) produced by the tumor cells; and administering an immune checkpoint inhibitor to the subject. Any of the methods may also comprise measuring CXCL 10.

A use of a compound represented by formula I, or a cis-trans isomer, enantiomer, diastereomer, racemate, solvate, hydrate, pharmaceutically acceptable salt or prodrug thereof in the preparation of a drug for preventing, relieving, assisting in treating, or treating lung injury. Upon verification, administration of the compound represented by formula I can significantly reduce proinflammatory cytokines, i.e., tumor necrosis factor α (TNF-α) and interleukin 6 (IL-6), of a rat model of acute lung injury, reduce the infiltration of inflammatory cells (comprising monocytes / macrophages, lymphocytes, and neutrophils) in lung tissues, relieve pathological injury of the lung tissues, improve the lung function, and increase the survival rate of comorbidities of acute lung injury. The compound represented by formula I can be used for preventing, relieving, assisting in treating, or treating lung injury, especially acute lung injury or comorbidities thereof, or acute respiratory distress syndrome or comorbidities thereof.

The invention provides an application of phosphatidylcholine 36: 1 in prevention and treatment of senescence cognitive impairment, and particularly relates to an application of phosphatidylcholine 36: 1 or a pharmaceutical composition containing phosphatidylcholine 36: 1 in preparation of drugs for prevention and / or treatment of senescence cognitive impairment. The phosphatidylcholine 36: 1 can improve the level of superoxide dismutase and glutathione peroxidase in the brain of the mouse and reduce the lipid oxidation level at the same time. After the phosphatidylcholine 36: 1 is used for treatment, the levels of inflammatory factors interleukin 1 beta, interleukin 6 and tumor necrosis factor alpha in the brain are obviously reduced. Meanwhile, neurotransmitter disorder in brains of senescent mice can be remarkably improved. After qRT-PCR analysis is carried out in the brain of a mouse, it is found that after phosphatidylcholine 36: 1 treatment, the senescence gene level is remarkably reduced, the pro-apoptosis gene level is remarkably reduced, and the anti-apoptosis gene level is remarkably increased. And after in vitro administration of phosphatidylcholine 36: 1 to mouse hippocampal neuronal cells, no cytotoxicity is found. Therefore, the phosphatidylcholine 36: 1 can be used for preventing and treating senescence cognitive impairment.

The application discloses an electrochemical sensor for detecting IBD protein markers and a preparation method thereof. The electrochemical sensor is composed of a CNT-embedded semi-cured PDMS flexible substrate, deposited gold nanoparticles and a nucleic acid sensing layer. The nucleic acid sensing layer comprises a tumor necrosis factor-alpha sensor, an interleukin 6 sensor, an interleukin 8 sensor, a transforming growth factor beta 1 sensor, a reference electrode and a counter electrode. The tumor necrosis factor-alpha sensor, the interleukin 6 sensor, the interleukin 8 sensor and the transforming growth factor beta 1 sensor all adopt single-stranded aptamers modified by a signal molecule methylene blue, and the nucleotide sequences corresponding to the single-stranded aptamers are SEQ ID NO. 1-4. The application can improve the modulus matching of the sensor and human tissue and excellent biocompatibility, realize accurate detection of low-concentration biomarkers and stable signal output of the sensor under a strain working condition.

The present invention provides a primary cell culture medium for culturing primary lung cancer epithelial cells, which contains at least one of an MST1 / 2 kinase inhibitor, a ROCK kinase inhibitor, a fibroblast growth factor 7, a B27 supplement, and a N2 supplement, a hepatocyte growth factor, an insulin-like growth factor 1, an interleukin 6, and a TGFβ type I receptor inhibitor. The present invention also relates to a culturing method using the primary cell culture medium and its application in drug efficacy evaluation and screening. The culturing method uses the above-mentioned primary cell culture medium to culture primary cells on a culture vessel coated with extracellular matrix glue, so that the primary cells proliferate rapidly. The cell model obtained by the primary cell culture medium and the primary cell culturing method of the present invention can be used for drug efficacy evaluation and screening.

The invention provides a special culture medium for prostate cancer organoid and a culture method thereof, and belongs to the technical field of biological medicines. The special culture medium for the prostatic cancer organoid is composed of a basic culture medium and a culture additive, and the basic culture medium does not contain exogenously added Noggin recombinant protein and R-spondin recombinant protein. The culture additive is prepared from a basic fibroblast growth factor, a keratinocyte growth factor, a fibroblast growth factor 10, insulin, a p38MAPK signal channel inhibitor, an insulin-like growth factor 1, B27, nicotinamide, N-acetylcysteine, hydrocortisone, a ROCK kinase inhibitor, retinoic acid, interleukin 6, prostaglandin E2, a eriocin and androgen. According to the special culture medium for the prostatic cancer organoid, the culture success rate is increased while the cost is reduced.

The present invention provides a cell population and a method for obtaining the same. The cell population of the present invention is obtained by culturing mononuclear cells derived from bone marrow, umbilical cord blood or peripheral blood in a culture medium containing four or less factors selected from stem cell factor, interleukin 6, FMS-like tyrosine kinase 3 ligand, thrombopoietin and vascular endothelial cell growth factor, and serum.

The disclosure relates to the in vitro use of the combined (i) measure of MDM2-encoding DNA and (ii) measure of interleukin 6 protein, in platelets, or in extracellular vesicles carried by platelets, of a subject, as a biomarker indicative of the occurrence of a cancer having chromatin-bound MDM2 in the said subject.

The invention discloses the application of L. pleurotus polysaccharide in the preparation of a drug for improving alcoholic liver damage, and relates to the field of biomedicine technology. The invention finds that L. pleurotus polysaccharide can effectively protect the liver cell structure, inhibit liver swelling caused by alcohol, and reduce the liver index; downregulate the activity of liver cell damage-related biological enzymes aspartate aminotransferase and alanine aminotransferase in serum; improve the activity of liver antioxidant enzymes, inhibit the generation of hepatocyte oxidation product malondialdehyde, and reduce the oxidative stress damage of the liver of alcoholic liver mice; at the same time, L. pleurotus polysaccharide can also reduce the levels of triglycerides and fatty acids in the liver and serum, effectively improve lipid metabolism disorders, and reduce lipid accumulation; in addition, L. pleurotus polysaccharide can reduce the release of inflammatory factors such as interleukin 6, interleukin 1β and tumor necrosis factor α, promote the body's inflammation level to restore the balance state, reduce liver inflammation, and thus improve the damage of alcohol to liver tissue.

Provided herein are methods for reducing risk of severe symptoms and outcomes associated with Coronavirus Disease 2019 (COVID-19) and Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection by measuring levels of interleukin 6 (IL-6), IL-8, IL-22, and serum ferritin in a subject. Also provided are methods for treating a subject exposed to or at elevated risk of expose to SARS-CoV-2 based on levels of IL-6, IL-8, IL-22, and ferritin in the serum of the subject.

The present invention provides a preparation method for extracting volatile oil of Chimonanthus chinensis leaves by ultrasonic-assisted steam distillation and its application in improving ulcerative colitis drugs. The method includes crushing Chimonanthus chinensis leaves to a specific particle size and then performing ultrasonic treatment and steam distillation under optimized conditions, and finally achieving 2.5% to 4% high-efficiency extraction. Volatile oil is rich in phellandrene, α-terpineol and (+)-limonene, accounting for more than 50% of the total mass. Pharmacological experiments show that this volatile oil can significantly reduce the levels of pro-inflammatory factors interleukin 6 (IL-6), interleukin 1β (IL-1β) and tumor necrosis factor α (TNF-α) in mouse serum, increase anti-inflammatory factor interleukin 10 (IL-10); increase the expression of tight junction protein ZO-1, protect the integrity of mouse intestinal epithelial barrier; and significantly downregulate the expression of proline hydroxylase 3 factor of HIF-1 pathway to inhibit inflammation.

The present invention discloses a recombinant nucleic acid molecule encoded by at least ORF (100, 100a) to reduce cytokine storm during immunotherapy. The recombinant nucleic acid molecule comprises at least one first hairpin ring structure, at least one second hairpin ring structure and a first promoter (120). The first hairpin loop structure is formed from one or more first short hairpin RNA (130a) sequences. The first hairpin ring structure modulates the amount of interleukin 6 (IL6) cytokine during immunotherapy. The second hairpin loop structure is formed from one or more second short hairpin RNA (130b) sequences. The second hairpin ring structure modulates the amount of granulocyte monocyte colony stimulating factor (GMCSF) cytokine during immunotherapy and is disposed upstream or downstream of the first hairpin ring structure. The first promoter (120) is disposed upstream of the first hairpin ring structure and the second hairpin ring structure.

The invention provides a diagnostic method for early recognition of fetal intrauterine infection, comprising: collecting a blood sample of a pregnant woman and at least one fetal body fluid sample selected from an amniotic fluid sample or an umbilical cord blood sample; performing quantitative detection on a plurality of inflammatory factors in the blood sample and the fetal body fluid sample through a multichannel immunological detection technology, wherein the inflammatory factors comprise interleukin 6, C-reactive protein, tumor necrosis factor alpha, interleukin 1 beta and interleukin 8; various inflammatory factors in a pregnant woman blood sample and a fetal body fluid sample are comprehensively detected, simultaneous analysis of the multiple factors is achieved, abnormal fluctuation of the inflammatory factors is captured in real time in combination with dynamic monitoring of concentration changes, and clinical symptoms of the pregnant woman are analyzed through comparison with clinical symptoms of the pregnant woman. And diagnosis results can be recorded through an electronic health record system and early warning is generated, so that doctors are supported to judge and intervene in time, and the risks of missed diagnosis and misdiagnosis are effectively reduced.

Disclosed herein are engineered extracellular vesicles for inhibiting 1L6 trans-signaling and VEGF- signaling comprising (a) an IL6 / IL6 receptor alpha complex-binding extracellular vesicle (EV) protein comprising a GP130 domain 1-3 protein portion, for binding IL6 / 1LR. receptor alpha complex, and a chimeric vesicle localization moiety, and (b) a VEGF-binding EV protein comprising at least two VEGFR- domain fusion units, for binding VEGF, and a chimeric vesicle localization moiety, wherein each VEGFR-domain fusion unit comprises an Ig-like domain 2 of a VEGF receptor 1 (VEGFR-1) linked to an Ig-like domain 3 of VEGF receptor 2 (VEGFR-2), and wherein the chimeric vesicle localization moiety comprises: (i) a surface-and-transmembrane domain of a first vesicle localization moiety, and (ii) a cytosolic domain of a second vesicle localization moiety, the method of making said vesicle and uses thereof,

The disclosure provides methods of preventing or treating heart failure in a mammalian subject, reducing risk factors associated with heart failure, and / or reducing the likelihood or severity of heart failure. The disclosure also provides methods of preventing, or treating LV remodeling in a mammalian subject, and / or reducing the likelihood or severity of LV remodeling. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide. In some embodiments, the methods comprise administering to the subject an effective amount of an aromatic cationic peptide to reduce levels of C-reactive protein, tumor necrosis factor alpha, interleukin 6, reactive oxygen species, Nt-pro BNP, and / or cardiac troponin I, and / or reduce expression levels of MLCL AT1 and / or ALCAT 1 in subjects in need thereof.

The present invention discloses a method for PEG site-specific modification of inflammatory markers and increasing protein stability, comprising the following steps: a purified protein in procalcitonin, C-reactive protein, amyloid A or interleukin 6 is mixed with mPEG2000Mal in a 5mmol / L phosphate buffer having a pH value of 7.2-7.4 until the reaction is complete. The conjugate is purified by a chromatographic column, and then rinsed by a proportioning liquid until it is flushed flat; then the proportioning liquid is used for elution, so that the sample is collected when the absorbance of the product increases; the collected sample is placed in an ultrafiltration centrifuge tube and centrifuged by a centrifugal device. The present invention selects a peg with a molecular weight of 2000, because its molecular weight is relatively small, it can partially penetrate into the protein for modification, which can also reduce immunogenicity relatively less while increasing protein stability.

The invention discloses a kit for detecting susceptibility and severity of children acute respiratory distress syndrome, and relates to the technical field of biomedical detection. The kit comprises a detection reagent combination and a standardized reference system, the detection reagent combination is prepared from specific binding angiogenin 2, a soluble advanced glycosylation end product receptor, pulmonary surfactant protein D, a soluble tumor necrosis factor receptor 1, interleukin 6, interleukin 8, a plasminogen activator inhibitor 1 and a capture and detection antibody of III type procollagen N-terminal peptide. The primer pair and the probe are used for specifically amplifying a single nucleotide polymorphism site rs4073 in a promoter region of the interleukin 8 gene; the standardized reference product system comprises gradient standard products covering the physiological concentration dynamic ranges of the markers on the 0th day, the 3rd day and the 7th day of morbidity; the kit is used for early-stage precise layering and dynamic prognosis evaluation of the acute respiratory distress syndrome of children.

The subject matter described herein relates to peptides that bind to the human AT-rich interactive domain 5A protein (Arid5a). The subject matter described herein also relates to methods of inhibiting Interleukin 6 (IL-6) production in a subject, the method comprising administering to the subject a pharmaceutical composition comprising a therapeutically effective amount of any one of the peptides disclosed herein.

A recombinant nucleic acid molecule is encoded at least by an ORF to lower a cytokine storm during immunotherapy. The recombinant nucleic acid molecule includes at least one hairpin loop structure and a first promoter. The at least one hairpin loop structure is formed by one or more short hairpin RNA sequences. The at least one hairpin loop structure regulates an amount of Interleukin 6 (IL6) cytokine during immunotherapy. The first promoter is disposed upstream of the at least one hairpin loop structure.

The disclosure relates to the in vitro use of the combined (i) measure of MDM2-encoding DNA and (ii) measure of interleukin 6 protein, in platelets, or in platelet-derived extracellular vesicles, of a subject, as a biomarker indicative of the occurrence of a cancer having chromatin-bound MDM2 in the said subject.

The present invention discloses a recombinant nucleic acid molecule encoded by at least ORFs (100, 100a) for reducing cytokine storm during immunotherapy. The recombinant nucleic acid molecule comprises at least one hairpin loop structure and a first promoter (120). The at least one hairpin loop structure is formed by one or more short hairpin RNA (130) sequences. The at least one hairpin loop structure regulates the amount of interleukin 6 (IL6) cytokine during immunotherapy. The first promoter (120) is located upstream of the at least one hairpin loop structure.

This invention provides an antibody combination for detecting interleukin-6 (IL-6), comprising a first antibody and / or a second antibody, each possessing a unique CDR fragment. Specific applications of this antibody combination are also provided. The advantages of this invention are that the antibody combination exhibits strong affinity for the IL-6 antigen, high detection sensitivity, ease of use, and rapid and stable detection. The concentration of IL-6 in normal human blood is approximately 4.2 pg / mL. Existing conventional low-affinity antibodies are insufficient for effective detection in this situation. However, the high-affinity antibody combination and the IL-6 quantitative detection kit containing this antibody combination using a double-antibody sandwich method provided by this invention can effectively achieve the quantitative detection of ultra-low concentrations of IL-6. Verification shows that the kit's sensitivity can reach 0.9 pg / mL.

The invention relates to the field of biological medicine, in particular to a preparation method of alpha-lactalbumin electrospun nanofiber loaded with cefalexin and epicatechin and application of the alpha-lactalbumin electrospun nanofiber as wound dressing to killing drug-resistant bacteria. Wound healing interruption caused by multi-drug-resistant bacterial infection is a difficult problem faced by a global medical health system, and due to the existence of drug resistance of antibacterial drugs, the problem may not be solved by a traditional treatment method. In order to solve the problem, the nanofiber prepared from cefalexin (CPL), epigallocatechin (EP) and alpha-lactalbumin (alpha-Lalb) through electrospinning is used as the dressing. Alpha-Lalb can promote migration and proliferation of fibroblasts and synthesis of collagen, scar formation is reduced, and the effect is excellent. CPL and EP have a synergistic inhibition effect on staphylococcus aureus (MRSA) and escherichia coli infection. Mature collagen exists at the wound, the number of inflammatory cytokines is small, vascular expression is increased, and expression of interleukin 6 is low. The dressing can meet individual requirements of infectious wound patients, and a non-invasive and easy-to-operate treatment scheme is provided.

The application discloses a kit for detecting interleukin 6 and preparation and application. The kit comprises magnetic microspheres coated first antibodies and tracer marker labeled second antibodies. The first antibodies are 12H6 with a catalog number of DA011, IL-6-55E9 with a catalog number of P1810035 of Jin Sui, or IL-6-01 with a catalog number of 20180915 of Gelin. The second antibodies are 15H5 with a catalog number of DA012, IL-6-55C6 with a catalog number of P1904008 of Jin Sui, or IL-6-02 with a catalog number of 20180919 of Gelin. The application has the advantages of simple operation, low cost, short detection time, high sensitivity and wide linear range, and can realize full-automatic, rapid, sensitive and quantitative detection of the concentration of IL-6 in samples.

The invention provides a composition for improving bone joints and promoting bone health as well as a preparation method and application thereof, and relates to the technical field of compositions. The composition is prepared from N-acetylglucosamine and a turmeric extract. The composition can improve the differentiation activity of cartilage precursor cells, effectively promote synthesis of cartilage matrixes, increase the structural construction ability of cartilage tissues, reverse expression down-regulation of cartilage synthesis markers, down-regulate abnormally high expression of cartilage decomposition markers and maintain metabolic balance of cartilage synthesis and decomposition, and has the effects of improving the cartilage tissue differentiation activity and improving the cartilage tissue differentiation activity. Abnormal high secretion of tumor necrosis factors alpha and interleukin 6 in LPS-induced cartilage cells is reduced, and the effects of resisting inflammation, resisting cartilage degradation and maintaining cartilage metabolism balance are achieved.